Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

New Market Research Report: Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022


Print article Print article
2014-03-20 15:58:59 - New Pharmaceuticals market report from GlobalData: "Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022"

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also

play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Full Report Details at
- www.fastmr.com/prod/782733_cimzia_crohns_disease_forecast_and_ma ..

UCB's Cimzia (certolizumab pegol) is a PEGylated Fab' fragment of a humanized mAb with specificity for human TNF-a. The Fab' fragment of this biologic was engineered with a single free cysteine residue in the hinge region, which enables The site-specific attachment of polyethylene glycol without affecting the ability of the Fab' fragment to bind to and neutralize TNF-a. Due to the absence of the Fc region in its structure, Cimzia does not cause antibody-dependent, cell-mediated cytotoxicity. Also, in contrast to Remicade and Humira, Cimzia does not increase apoptosis, a well-known phenomenon with other anti-TNF-a agents, which may be responsible for their associated side effects.

Report Scope

* Overview of Crohn's disease (CD), including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Cimzia including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Cimzia for the top seven countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, China and Canada

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Cimzia performance
* Obtain sales forecast for Cimzia from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, China and Canada)

Report Table of Contents:

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.2 Symptoms 15
3.3 Prognosis 16
3.4 Quality of Life 16
4 Disease Management 17
4.1 Treatment Overview 18
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 24
6 Cimzia (certolizumab pegol) 26
6.1 Overview 26
6.2 Efficacy 27
6.3 Safety 27
6.4 SWOT Analysis 28
6.5 Forecast 29
7 Appendix 31
7.1 Bibliography 31
7.2 Abbreviations 34
7.3 Methodology 36
7.4 Forecasting Methodology 36
7.4.1 Diagnosed CD Patients 36
7.4.2 Percent Drug-Treated Patients 37
7.4.3 General Pricing Assumptions 37
7.4.4 Individual Drug Assumptions 39
7.4.5 Generic Erosion 39
7.5 Physicians and Specialists Included in This Study 40
7.6 Primary Research - Prescriber Survey 42
7.7 About the Authors 43
7.7.1 Author/Reviewer 43
7.7.2 Global Head of Healthcare 43
7.8 About GlobalData 44
7.9 Disclaimer 44


List of Tables

1.1 List of Tables
Table 1: Symptoms of CD 15
Table 2: Treatment Guidelines for CD 19
Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013 21
Table 4: Leading Branded Drugs Used to Treat CD 25
Table 5: Product Profile - Cimzia 27
Table 6: Cimzia SWOT Analysis, 2013 29
Table 7: Global Sales Forecasts ($) for Cimzia, 2012-2022 30
Table 8: Physicians Surveyed, By Country 42

List of Figures

1.2 List of Figures
Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right) 12
Figure 2: Potential Biologic Drug Targets for CD 14
Figure 3: Patient Care Path for CD 20

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com